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ABSTRACT
Introduction: Cardiovascular disease is the
leading cause of death worldwide, with
coronary heart disease being the most
common manifestation. While deaths
attributed to coronary heart disease are falling
in the developed world, the number of patients
with cardiomyopathy continues to increase. In
this paper, the current literature on imaging
modalities for inﬁltrative and inﬂammatory
cardiomyopathies is reviewed, focusing on the
three most common diagnoses, namely
sarcoidosis, amyloidosis, and myocarditis.
Case report: A 43-year-old male presented with
palpitations and left ventricular systolic
dysfunction for a second opinion following an
initial nondiagnostic workup. The employed
clinical and radiologic approach that led to a
deﬁnitive diagnosis and disease-speciﬁc
treatment is presented here.
Conclusion: The current algorithms and the
strengths and weaknesses of the various radiologic
techniques in establishing a diagnosis in patients
who present with new onset cardiomyopathy
are reviewed. Recommendations are provided
regarding the selection between echocardiography,
computed tomography radionuclide imaging,
and magnetic resonance imaging in diagnosing the
various causes of cardiomyopathy.
Keywords: Amyloidosis; Cardiomyopathy;
Computed tomography; Echocardiography;
Magnetic resonance imaging; Myocarditis;
Radionuclide imaging; Sarcoidosis
INTRODUCTION
Cardiovascular disease is the leading cause of
death worldwide [1]. From 1990 to 2010, the
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has risen by 31% contributing to over
15,616,000 deaths worldwide in the year 2010
[2]. Speciﬁcally with the prevalence of
cardiomyopathies rising by 40%, early
diagnosis is critical in directing treatment and
following progression of the disease [2, 3].
Given nonspeciﬁc symptoms and baseline
tests, noninvasive imaging with
echocardiography, cardiac magnetic resonance
imaging (CMRI) and positron emission
tomography (PET)-computed tomography (CT)
performed with ﬂuorine-18-ﬂuoro-deoxy-
glucose (FDG-PET-CT) is instrumental [1]. This
report describes a case of cardiac sarcoidosis
focusing on workup that led to the diagnosis. It
also gives an overview of three of the most
common cardiomyopathies: amyloidosis,
myocarditis, and sarcoidosis and their workup
with various imaging modalities namely
echocardiography, CMRI, and FDG-PET.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies with human or
animal subjects performed by any of the
authors.
CASE REPORT
A 43-year-old Caucasian man with history of
premature ventricular contractions (PVCs) and
mild-moderate left ventricular (LV) systolic
dysfunction with normal LV dimensions on
echocardiogram performed at an outside
institution was admitted from the clinic after a
second opinion with a chief complaint of
increasing palpitations over a period of
2 months. The patient did not smoke, denied
chest discomfort, shortness of breath with daily
activities, paroxysmal nocturnal dyspnea, and
orthopnea. There was no history of
hypertension, dyslipidemia, coronary artery
disease (CAD), and no family history of
premature CAD or stroke. The patient also did
not have a recent history of severe illness,
respiratory or otherwise, or travel outside of
the United States.
On physical examination, the patient
appeared physically ﬁt in no apparent distress.
The vital signs were temperature 97.8 F, blood
pressure 137/71 mmHg, heart rate 45 beats/min
(bpm), respiratory rate 18 breathes/minute, and
oxygen saturation 100% on room air. There was
no jugular venous distention and no carotid
bruits. Lungs were clear to auscultation.
Palpation of the heart was unremarkable. The
heart rate was regular with an occasional
premature beat. The ﬁrst and second heart
sounds were normal, and no murmurs, rubs,
or gallops were appreciated. The abdomen was
soft, nontender, nondistended, with no
hepatosplenomegaly. There was no peripheral
clubbing, cyanosis, or edema. No skin lesions
were noted.
Laboratories were notable only for
hyperlipidemia (Table 1); cardiac troponin T,
creatine kinase (CK), CK-myocardial band, and
brain natriuretic peptide were all within normal
limits. The 12-lead electrocardiogram (ECG)
demonstrated a junctional rhythm with
frequent PVCs and a right bundle branch
morphology (Fig. 1). Repeat echocardiography
was notable for mild-moderate dilation of the
left ventricle, with overall mild-moderate
reduction of LV systolic function with an
ejection fraction (EF) of 40%. The basal-to-mid
inferoposterior wall was akinetic, and the
inferior wall and apex were severely
hypokinetic. The LV wall thickness was
normal and the right ventricular (RV) size and
function, atria, pericardium, and pleura were
each normal. A standard Bruce Protocol exercise
stress test was carried out to assess for potential
underlying etiology that led to the patient’s
182 Cardiol Ther (2013) 2:181–197
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exercised for 15 min and 15 s, achieving a
maximum heart rate of 160 bpm (90% of the
maximum predicted for the patient’s age) and
blood pressure of 166/70 mmHg. No ischemic
symptoms or ST-segment changes were noted.
There were multiple PVCs present during
exercise with triplets and three 5-beat runs of
Table 1 Admission laboratory values
Results Reference range
Cardiac tests
Brain natriuretic peptide 37 0–100 (pg/mL)
Creatine kinase 129, 91, 118 41–266 (U/L)
Creatine kinase-myocardial band 0.7, 0.7, 2.0 0.0–6.6 (ng/mL)
Myoglobin 24.08 0–100 (ng/mL)
Troponin \0.04 (93) 0.00–0.04 (ng/mL)
Complete blood count
White blood cells 5.18 4–10 (K/lL)
Hematocrit 39.1 40–54 (%)
Platelets 222 150–450 (K/lL)
Lipid test
Cholesterol 235 140–199 (mg/dL)
Triglycerides 145 35–150 (mg/dL)
HDL cholesterol 57 40–100 (mg/dL)
LDL cholesterol calculated 149 50–129 (mg/dL)
Chemistry
Sodium 138 136–145 (mmol/L)
Potassium 3.7 3.4–5.0 (mmol/L)
Chloride 107 98–107 (mmol/L)
Carbon dioxide 22 22–31 (mmol/L)
Blood urea nitrogen 18 6–23 (mg/dL)
Creatinine 0.94 0.50–1.20 (mg/dL)
Glomerular ﬁltration rate 88 NA
Glucose 94 70–100 (mg/dL)
Liver function tests
Alanine aminotransferase 16 10–50 (U/L)
Aspartate aminotransferase 15 10–50 (U/L)
Alkaline phosphatase 47 35–130 (U/L)
Bilirubin 0.6 0.0–1.0 (mg/dL)
Infectious
Lyme antibody Negative Negative
Human Immunodeﬁciency Virus-Antibody Nonreactive Nonreactive
Immunology
C-reactive protein 0.8 0.0–3.0 (mg/dL)
Erythrocyte sedimentation rate 4 0–12 (mm/h)
HDL High density lipoprotein, LDL low density lipoprotein
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123nonsustained ventricular tachycardia (VT)
during the recovery period.
A diagnostic right and left heart
catheterization with coronary angiography was
performed. The ﬁlling pressures (mmHg) were
as follows: right atrium 10/9, right ventricle
28/4, pulmonary artery 26/10, pulmonary
capillary wedge pressure 14 with ventricular
waves to 18, LV end diastolic pressure 12, aorta
126/76 with no gradient on pull-back across the
aortic valve. The wave forms were not
suggestive of a restrictive pattern. Coronary
angiography revealed no signiﬁcant CAD
(Fig. 2).
DISCUSSION
Among patients with a nondilated
cardiomyopathy in whom CAD has been
excluded, the differential diagnosis includes
inﬁltrative cardiomyopathies such as
sarcoidosis and amyloidosis. Inﬂammatory
cardiomyopathy, such as myocarditis, should
also be considered. It is important to distinguish
between these etiologies since the window of
intervention and treatment options remains
variable.
Imaging
Noninvasive imaging techniques play a critical
role in screening and diagnosing these diseases
[1]. Echocardiography is a widely available
noninvasive imaging technique; however, it
has limited speciﬁcity in diagnosing inﬁltrative
and inﬂammatory cardiomyopathies [5].
Although morphologic and functional features
of the heart in restrictive cardiomyopathy can
Fig. 1 Resting 12-lead electrocardiogram. There is junc-
tional rhythm at 57 bpm with retrograde conduction at the
P-wave (arrow), and frequent premature ventricular con-
tractions with a right bundle branch pattern. The QRS
duration is mildly prolonged at 106 ms (ms), QT/QTc
426/414 ms, and QRS Axis -67 consistent with a left
anterior fascicular block
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123be well characterized by echocardiography, it
has relatively poor spatial and contrast
resolution [5]. Although newer techniques
such as doppler, strain, and speckle
echocardiography are useful in detecting
abnormal myocardial activity, these imaging
modalities cannot delineate tissue
characteristics and therefore cannot
differentiate between various types of
cardiomyopathies [5].
For inﬂammatory diseases and
cardiomyopathy, more speciﬁc cross-sectional
tissue imaging is required [1]. CMRI has proven
to be instrumental in the diagnosis of
myocardial and pericardial diseases due to its
noninvasiveness, lack of radiation, tomographic
imaging, reproducibility, and high spatial
resolution [6].
PET-CT can identify an inﬂammatory process
even before structural changes are apparent on
CT scanning [7]. PET performed with FDG
identiﬁes metabolically active tissue and
complements the cross-sectional imaging
modalities that provide anatomical features
[7]. When patients present with nonspeciﬁc
symptoms that are difﬁcult to evaluate with
routine imaging modalities, whole body
imaging with FDG-PET-CT becomes
instrumental [7].
Amyloidosis
Systemic amyloidosis results from deposition of
misfolded, insoluble protein throughout the
body [8]. Cardiac amyloidosis is common in
immunoglobulin amyloid light-chain (AL) and
transthyretin (TTR) types of amyloidosis. It is
caused by deposition of glycoproteins in
myocardial interstitium [8]. This leads to
concentric thickening of the myocardium and
impaired contractility and diastolic dysfunction
with restrictive features which in turn can lead
to arrhythmias and sudden death [6, 8, 9].
Diagnosis is made by positive endomyocardial
biopsy or biopsy of any other organ combined
with typical features on cardiac imaging [1]. The
mainstay of treatment of amyloidosis is
supportive, with use of high-dose diuretics for
heart failure that results from restrictive
pathophysiology [10]. Given the high rates of
Fig. 2 Coronary angiography. There is right dominant circulation with normal left main coronary artery, left anterior
descending artery, and left circumﬂex artery with no signiﬁcant lesions
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123arrhythmias, there is low threshold for
introducing implantable cardiac deﬁbrillators
and prophylactic antiarrhythmics; however,
there are limited data that demonstrate
efﬁcacy of these interventions [10]. In AL
amyloidosis, chemotherapy has been shown to
enhance survival [10]. For TTR amyloidosis,
liver transplantation is the standard treatment
to remove the main source of plasma TTR [10].
Two-dimensional echocardiography (2D
echo) can be used to assess structural anatomy
and LV function in cardiac amyloid [11].
Usually all four chambers are involved and
thickening of the inter-atrial septum and right
atrial free wall is highly speciﬁc for amyloidosis
[12]. Features suggestive of amyloidosis on 2D
echo are thickened myocardium (from amyloid
deposition in the interstitial space) with
increased myocardial echogenicity and
granular speckling [12]. One study compared
patients with documented cardiac amyloidosis
with controls noting that presence of LV
hypertrophy corresponds with sensitivity of
87% and speciﬁcity of 81% when increased
echogenicity is observed [12]. The speciﬁcity
rose to 100% if increased atrial thickness was
also present [12]. Other features that may also
be present include thickened RV myocardium,
decreased ventricular cavity size, bi-atrial
enlargement, and the presence of pericardial
effusion [11], ﬁndings more often present in
advanced disease.
The most commonly used radionuclide
imaging technique in cardiac amyloidosis is
bone imaging tracer (Tc-99 m pyrophosphate
[PYP] or Tc-99m 3,3-diphosphono-1,2-
propanodicarboxylic acid [DPD]) [13, 14] and
single photon emission computed tomography
(SPECT) tracer I
123-metaiodobenzylguanidine
(MIBG) [9]. MIBG is an analogue of a
neurotransmitter which accumulates in nerve
endings and assesses sympathetic nerve activity
[9]. MIBG uptake is recorded early at 15 min and
later at 4 h (delayed) to assess distribution of
sympathetic innervation and degree of
impairment of sympathetic nerve impairment
[9]. A decrease in MIBG accumulation correlates
with severity of amyloid accumulation in
patients with familial amyloid polyneuropathy
[15]. Although PET tracers show promise by
providing better myocardial-sympathetic
nervous system innervation, resolution and
quantiﬁcation, thus far no PET tracers speciﬁc
for amyloidosis have been identiﬁed. FDG is not
ideal for imaging amyloidosis since it is a
metabolic tracer and does not bind to amyloid
protein [9].
CMRI is effective in detecting early stages of
amyloidosis [10]. The typical features of cardiac
amyloidosis such as increased LV wall thickness,
bi-atrial enlargement, and pericardial effusions,
are well imaged with CMRI [8]. Late gadolinium
enhancement and gadolinium kinetics are also
useful in assessing severity of amyloid burden
and predicting mortality [8]. Delayed
enhancement can also be seen in imaging due
to increased retention of contrast by expansion
of the interstitial space in the amyloid rich area
[8]. This results in a classic diffuse, global
subendocardial delayed enhancement pattern
in a nonvascular distribution [8]. This diffuse
heterogeneous enhancement along with
biventricular subendocardial enhancement
leads to a striped appearance seen in cardiac
amyloidosis [6]. Expansion of the extracellular
volume can be well imaged with CMRI and has
been recently proposed as an early feature of
cardiac amyloidosis [16, 17].
Myocarditis
Myocarditis is an acute or chronic inﬂammation
of myocardium caused by a variety of processes
including infections, systemic diseases, drugs,
186 Cardiol Ther (2013) 2:181–197
123or toxins [1, 18]. Most patients are
asymptomatic; however, chest pain,
arrhythmias, and rapid onset heart failure
have been documented [1]. Furthermore,
myocarditis is a major cause of sudden death
in adults \40 years of age [18]. Because the
symptoms of myocarditis are nonspeciﬁc,
myocardial biopsy is the only means of
making the diagnosis [19]. Focal, mild
myocarditis may resolve spontaneously, but
mortality of fulminant myocarditis is at least
40% in the ﬁrst 4 weeks and survival rate of
patients with untreated giant cell and
eosinophilic myocarditis is 20% in 4 years [19].
If undiagnosed, granulomatous necrotizing
myocarditis is fatal [19]. In severe cases,
implantation of a ventricular assist device or
even heart transplantation may be necessary
[20]. Arriving at an early diagnosis is critical
since treatment options vary depending on the
causative etiology of myocarditis [20]. In acute,
chronic and fulminant viral myocarditis,
immunosuppression with steroids and
intravenous immunoglobulin has been shown
to improve outcome [20]. In the rare and often
rapidly fatal cases of giant cell myocarditis,
where diagnosis is frequently missed until
autopsy, initiation of early treatment is critical
[21]. Immunosuppressive therapy with triple
combination of cyclosporine, azathioprine, and
corticosteroids ﬁrst established in 1990s by
Multicenter GCM study group has remained
the choice of treatment to achieve remission
deﬁned as survival free of heart transplantation
[21, 22].
Viral myocarditis is an important cause of
myocarditis in North America and Europe [18].
Histologically, this involves focal myocardial
apoptosis, necrosis, macrophage activation and
tissue edema [1]. Myocarditis involves three
phases, namely acute phase characterized by
virus entry, subacute phase involving B and T
lymphocyte activation and lastly the chronic
phase of myocardial remodeling and
development of dilated cardiomyopathy [23].
Although endomyocardial biopsy revealing
inﬁltrative lymphocytes and myocytolysis is
considered the gold standard, it is limited in
sensitivity and speciﬁcity [18].
Since there are no speciﬁc features of
myocarditis on echocardiography, 2D echo is
mainly used to rule out other causes of heart
failure such as valvular, congenital or
pericardial cardiovascular disease [24]. LV
systolic dysfunction is commonly seen in
myocarditis; however, RV systolic dysfunction
is the most important predictor of death [24].
Furthermore, echocardiography can be used to
identify acute versus fulminant myocarditis.
Acute myocarditis presents with LV dilation,
decreased LV function, and normal LV
thickness, whereas in fulminant myocarditis
LV is not dilated, but is thickened and
hypocontractile [25].
The inﬂammatory pathophysiology
underlying myocarditis may be depicted as
increased metabolic activity on PET-CT [7].
Myocardial FDG uptake may vary depending
on the cause of myocarditis [7]. For example,
radiation and chemotherapy are believed to
cause microvascular damage leading to
impaired perfusion and fatty acid metabolism
necessitating switch to high glucose
metabolism [22–26]. This may lead to regional
or uniform global myocardial involvement [7].
Myocardial inﬂammation from viral infection
(chronic Epstein-Barr virus) may result in
increased heterogeneous FDG uptake [27].
Exposure to anthracyclines causes myocardial
necrosis also leading to abnormal FDG uptake
in the myocardium [6, 7].
Cardiac MR is the most accurate noninvasive
imaging modality to diagnose myocarditis with
sensitivity and speciﬁcity of 100% ﬁrst reported
Cardiol Ther (2013) 2:181–197 187
123by Gagliardi et al. [28] in a cohort of 75
pediatric patients, and reproduced thereafter
in other studies with similar results in adults
with myocarditis [25]. In the acute and subacute
phases, gadolinium-enhanced double-
inversion-recovery fast-spin-echo (DIR-FSE) T2-
and T1-weighted images show areas of
enhancement in the epicardial regions of the
left ventricle, septum, and right ventricle [1,
29]. Increased signal intensity is seen for up to
4 weeks after inﬂammation has begun [1].
Delayed gadolinium enhancement imaging is
useful in acute phase of myocarditis before
irreversible damage has occurred or in the
chronic phase where ﬁbrotic changes have
taken place [1]. Hyperenhancing nodules and
transmural involvement are common with
subepicardial, centromyocardial or mixed
myocardial enhancement [30].
Sarcoidosis
Sarcoidosis is a systemic granulomatous disease
of unknown etiology [31]. Although only 5% of
cases involve the heart, patients may present
with acute cardiac failure, arrhythmias or
sudden death [31]. Cardiac sarcoidosis has
three histologic phases: edema, granulomatous
inﬁltration, and ﬁbrosis and eventual scarring
[32]. Usually involvement is predominantly
myocardial affecting the LV free wall, basal
septum, right ventricle, and ﬁnally the atrial
wall [1, 31]. This predisposition is believed to be
due to increased myocardial mass in these areas
[31].
Standard diagnostic criteria for cardiac
sarcoidosis developed by the Japanese Ministry
of Health and Welfare lack sensitivity and
speciﬁcity in the absence of diagnostic
myocardial biopsy (Table 2)[ 33, 34]. Even
though the gold standard of diagnosis is
myocardial biopsy, it has limited utility due to
its invasive nature and high false-negative rate
secondary to patchy cardiac inﬁltration [35].
In its early stages, cardiac sarcoidosis is
usually clinically silent, rapidly progressing to
heart failure, arrhythmias, and even sudden
cardiac death [36]. Currently, there are no
Table 2 Modiﬁed Japanese Ministry of Health and Welfare guidelines for diagnosing cardiac sarcoidosis
1. Histologic diagnosis group: endomyocardial biopsy demonstrates epithelioid granulomata without caseating granulomata
2. Clinical diagnosis group: in patients with histologic diagnosis of extracardiac sarcoidosis, cardiac sarcoidosis is
suspected when ‘a’ and at least one of criteria ‘b’ to ‘d’ is present, and other etiologies such as hypertension and coronary
artery disease have been excluded:
a. Complete right branch bundle block (BBB), left BBB, left-axis deviation, atrioventricular block, ventricular
tachycardia, premature ventricular contractions or pathological Q- or ST-T change on resting, or ambulatory
electrocardiogram
b. Abnormal wall motion, regional wall thinning, or dilation of the left ventricle
c. Perfusion defect by
201thallium-myocardial scintigraphy or abnormal accumulation by 67 Ga-citrate or 99mTc-PYP
myocardial scintigraphy
d. Abnormal intracardiac pressure, low cardiac output, or abnormal wall motion or depressed ejection fraction of the
left ventricle
Reproduced with permission from Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of
gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol.
2005;45:1683–90
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approach [36]. However, in a recent review
article by Mantini et al. [36], a step-wise
algorithm for patients with suspected cardiac
sarcoidosis was proposed. According to the
algorithm, patients with proven extra-cardiac
sarcoid or patients with suspected sarcoid
should be screened with detailed history,
physical examination, ECG, and chest X-ray
[36]. If the patient is symptomatic, the ECG is
abnormal (VT, Mobitz type II or complete heart
block on 12-lead,[100 PVCs on 24-hour Holter
monitor, or T-wave alternans) or X-ray
demonstrates cardiomegaly, follow-up testing
is recommended [36]. In a patient with extra-
cardiac sarcoid, with no CAD by angiography,
further imaging with CMRI, 18F-FDG-PET,
rest/stress technetium-99m (
99mTc) sestamibi,
or 201-thallium (TI) plus 67-gallium is
recommended [36]. If any of the imaging
results are abnormal, treatment with steroids
should be initiated. Although no randomized
controlled studies have demonstrated efﬁcacy
of steroid treatment, small cohort studies have
shown beneﬁts of oral prednisone at doses
30–60 mg/day for 8–12 weeks with gradual
tapering 10–20 mg/day for 6–12 months [36, 37].
Dosing should also be adjusted to counteract
known side effects associated with prolonged
steroid which include infection, osteoporosis,
myopathy, weight gain, and mood changes
[36–38]. Furthermore, if the ECG shows type II
second-degree or complete atrioventricular block,
sustained VT or EF\50% on echocardiography
implantable cardioverter-deﬁbrillator (ICD)
placement is recommended [36, 38].
Two-dimensional echocardiographic
ﬁndings of cardiac sarcoidosis include septal
thickening or thinning, general wall motion
abnormalities, local aneurysms, LV dilation and
systolic dysfunction, or pulmonary artery
hypertension [39, 40]. However, myocardial
abnormalities earlier on in the disease
progression cannot be appreciated on 2D echo.
On PET-CT, active necrotizing
granulomatous disease shows up as increased
18F-FDG uptake in myocardium with
nonperivascular distribution [1, 41]. This is a
particularly useful imaging modality to identify
early stages of disease where inﬂammatory
activity is high but myocardial damage is not
yet evident. Also, combined imaging of
myocardial perfusion (using TI or
99mTc
SPECT, rubidium-82 or N-13 ammonia PET)
and FDG imaging can help differentiate
myocardial scar from active myocardial
sarcoidosis, and identify various stages of the
disease process (Fig. 3)[ 42]. In a study of 22
patients with systemic sarcoidosis, PET-CT had
a reported sensitivity and speciﬁcity of 100%
and 95.5% for diagnosing cardiac sarcoidosis
[41]. Since many patients with sarcoidosis
require cardiac pacemakers or deﬁbrillators to
manage arrhythmias (a contraindication to MR
imaging prior to the recent introduction of MRI
compatible devices), PET-CT becomes the
preferred imaging modality to monitor the
disease over time in these patients [7]. CMRI
has been shown to be a cost-effective diagnostic
technique in evaluating cardiac involvement in
sarcoidosis and response to therapy [34]. In a
series of 58 patients with biopsy-proven
pulmonary sarcoidosis who were being
assessed for cardiac sarcoidosis, the sensitivity
and speciﬁcity of CMRI were 100% and 78%,
respectively [34]. On DIR-FSE T2-weighted
imaging, the initial edematous phase is seen as
localized enhancement of signal intensity and
area of hyperintensity within myocardium [1,
35]. Active inﬂammation appears as delayed
enhancement on inversion recovery prepared
gradient-echo T1-weighted images [34] and as a
focus on cine imaging and bright on DIR-FSE
T2-weighted imaging [1]. Scarred segments
Cardiol Ther (2013) 2:181–197 189
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with regional loss of wall thickness and
hypokinesis [1, 34].
The major ﬁndings of amyloidosis,
myocarditis and sarcoidosis with
echocardiography, FDG-PET-CT, and cardiac
MRI are summarized in Table 3 [1, 7–14, 16,
17, 22–26, 29, 30, 34, 39–41].
CASE WORKUP
Given the patient’s gender, age, and symptoms,
the patient had intermediate pretest probability
for CAD and cardiac catheterization was an
acceptable diagnostic approach [43]. With the
normal coronary angiography, our suspicion for
inﬁltrative cardiomyopathy was high. RV
endomyocardial biopsy demonstrated mild
focal myocyte hypertrophy and mild focal
interstitial ﬁbrosis with no evidence of active
myocarditis, granulomatous inﬂammation,
acute or recent myocardial infarction, amyloid
heart disease, or iron deposition. However,
since endomyocardial biopsy has a high false-
negative rate in cardiac sarcoidosis (due to the
focal disease process), we used cardiac MRI
and PET-CT to further characterize the
pathology due to their high sensitivity for
detecting inﬁltrative and inﬂammatory
cardiomyopathies (Table 4)[ 12, 22, 29, 35, 41].
Given the reduced LV EF, patient’s symptoms
and discordant evaluation from cardiac
catheterization, patient met appropriate
criteria for use of delayed enhancement and
CMRI [44]. CMRI showed akinesis of the basal
inferolateral walls with corresponding delayed
Fig. 3 Perfusion and ﬂuorine-18-ﬂuoro-deoxy-glucose
uptake in cardiac sarcoidosis. Perfusion and metabolism
patterns in various stages of cardiac sarcoidosis. Reproduced
with permission from Skali H, Schulman AR, Dorbala S.
(18)F-FDG PET/CT for the assessment of myocardial
sarcoidosis. Curr Cardiol Rep. 2013;15:352
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123hyperenhancement of gadolinium (Fig. 4,
Movie 1). With these abnormal imaging
results, patient met appropriate criteria for the
routine use of radionuclide imaging [43]. FDG-
PET-CT showed focal areas of active
inﬂammation in the basal inferolateral walls
and focal increased uptake in the mediastinal
lymph nodes. Chest CT scan obtained for
attenuation correction of the FDG-PET-CT
images showed evidence of lymphadenopathy
(Fig. 5, Movie 2). Lymph node biopsy was
consistent with ‘burnt-out’ hyalinized
granulomas and conﬁrmed the diagnosis of
sarcoidosis (Fig. 6). The patient was diagnosed
with cardiac sarcoidosis and was treated with
prednisone (60 mg orally daily for 7 months).
Given the history of ventricular arrhythmia
during exercise stress test in this patient with
mild-to-moderate LV systolic dysfunction, a
dual-chamber pacemaker (DDD) with
deﬁbrillator, programmed to treat arrhythmias
faster than 170 bpm and DDD with a lower rate
limit of 70 bpm, was placed to provide pacing
support and prophylaxis against ventricular
arrhythmias. The patient was followed initially
at 3 months, then every 6 months clinically and
with follow-up FDG-PET-CT imaging. Cardiac
imaging of the patient showed a continuing
stable function. The patient experienced one
episode of appropriate deﬁbrillator discharge
while watching a sports match.
At follow-up 1 year later, the patient was
doing well—with no chest pain, shortness of
breath, and no skin, ocular or joint
manifestations of sarcoidosis. The patient had
normal lung function and now met criteria of
New York Heart Association class I (NYHA class
I) heart function with no fatigue, palpitations,
or dyspnea and otherwise no limitation of
physical activity [45]. Given the signiﬁcant
reduction in risk of ICD shock therapy with
class III antiarrhythmics versus beta-blockers
[46], the recommendation by the
electrophysiologist was to initiate sotalol.
Repeat imaging with FDG-PET-CT rubidium-82
showed unchanged area of medium-sized focal
Table 4 Sensitivity and speciﬁcity of imaging studies
Echocardiography MRI FDG-PET
Sarcoidosis
Sensitivity (%) Low 100 100
Speciﬁcity (%) 78 95
Amyloidosis
Sensitivity (%) 87 N/A N/A
Speciﬁcity (%) 81
Myocarditis
Sensitivity (%) Low 100 N/A
Speciﬁcity (%) 100
Adapted from [12, 22, 29, 34, 41]
FDG-PET Fluorine-18-ﬂuoro-deoxy-glucose positron
emission tomography, MRI magnetic resonance imaging
Fig. 4 Cardiac magnetic resonance imaging with focal late
gadolinium enhancement suggesting focal inﬂammation.
There is strong accumulation of late gadolinium enhance-
ment involving the basal and mid inferior wall and basal
and mid-lateral wall as well as another focus in the basal
septum. The pattern of enhancement involves the mid-
myocardium and epicardium
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123FDG uptake in the basal inferolateral wall
suggestive of stable active cardiac sarcoid and
a persistent prevascular lymph node measuring
0.7–1.2 cmnowdemonstratingmildFDGactivity
consistent with likely mildly active sarcoid.
CONCLUSION
The case of a 43-year-old male with nonspeciﬁc
symptoms of palpitations and left ventricular
systolic dysfunction is presented here; the
initial workup with echocardiography, exercise
stress test, and coronary angiography were
nondiagnostic. Given a high suspicion for
inﬁltrative cardiomyopathy, CMRI was used to
characterize cardiac wall motion abnormalities,
FDG-PET-CT and subsequent cardiac and lymph
node biopsies were performed to conﬁrm the
diagnosis of cardiac sarcoidosis.
Brief etiologies of two other common
cardiomyopathies, namely amyloidosis and
Fig. 5 Myocardial perfusion using rubidium-82 and myo-
cardial ﬂuorine-18-ﬂuoro-deoxy-glucose (FDG) uptake.
Uptake is shown in the corresponding segments in alternate
rows shown as short axis, horizontal long axis and vertical
long axis images. There is a small-to-medium sized
perfusion defect involving, the basal inferior wall, basal
and mid inferolateral walls. The basal inferior and
inferolateral walls show mild mismatch (rest perfusion
defect with minimal FDG uptake). There is also increased
FDG uptake without a perfusion defect in the regions of
the mid-lateral wall, the basal anteroseptal, anterior, and
anterolateral walls
Fig. 6 Histopathology. Lymph node specimen consistent
with ‘burn-out’ hyalinized ﬁbrous granulomas with dys-
trophic calciﬁcations
194 Cardiol Ther (2013) 2:181–197
123myocarditis, were also reviewed. The advantages
and disadvantages of echocardiography,
computed tomography radionuclide imaging,
and magnetic resonance imaging in working up
these cardiomyopathies were discussed and
current algorithms, which are helpful to establish
a deﬁnitive diagnosis, were also described.
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